Xencor XNCR 深 滬
等待開盤 12-24 09:30:00 美东时间
15.47
-0.500
-3.13%
華盛通- 最 高16.04
- 今 開15.74
- 成交量 54.69万股
- 最 低 15.22
- 昨 收 15.97
- 總市值 11.03亿
- 52周最高 24.6599
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.92
- 委 比 -42.20%
- 總股本 7132.30万
- 歷史最高 58.345
- 量 比 0.48
- 振 幅 5.13%
- 歷史最低 5.75
- 每 手 1
- 風險率 4.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xencor Faces Structural Headwinds As Long-Term Momentum Fades
Why Xencor Stock's current weakness may persist and why rallies ahead are unlikely to sustain.
12-18 19:25
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Barclays Maintains Overweight on Xencor, Raises Price Target to $26
Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $23 to $26.
12-18 02:01
Incyte announces EU approval of Xencor-partnered lymphoma therapy
Incyte (INCY) announced on Wednesday that the European Commission approved a drug regimen containing its Xencor (XNCR)-partnered antibody drug Minjuvi as a late-line option for certain adults with fol...
12-18 00:52
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases
Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Study ...
12-17 00:30
Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which
12-09 20:11
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Submits Recalculated Initial Offer of $4.75 Based on Board's Value Destructive Actions Nominated Two Independent Candidates to Restore Oversight and Protect Shareholders Urges Shareholders t...
12-03 07:48
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $29
Truist Securities analyst Gregory Renza initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $29.
11-25 02:04
Candel pausing development of CAN-2409 in prostate cancer type
Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing. The company...
11-15 00:47
